Ultragenyx, Arcturus in Potential $1.56B+ Rare Disease Collaboration

Home/Financial/Ultragenyx, Arcturus in Potential $1.56B+ Rare Disease Collaboration

Ultragenyx, Arcturus in Potential $1.56B+ Rare Disease Collaboration

Coverage of the Big3Bio-area companies’ launching of an up-to-$1.56B+ rare disease collaboration:

BioWorld: Ultragenyx gives Arcturus rocket shot in potential $1.57B deal
“The up front is only $10 million, but Arcturus Therapeutics Inc. stands to collect up to $1.56 billion more from Ultragenyx Pharmaceutical Inc. in a rare disease research collaboration and license deal to discover and develop messenger RNA (mRNA) therapeutics using its unlocked nucleomonomer agent (UNA) oligomer chemistry and Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR) nanoparticle delivery platform.” Full article

GEN: Ultragenyx, Arcturus Launch Up-to-$1.56B+ Rare Disease Collaboration
“This collaboration with Arcturus will help us address a wider range of rare diseases than is possible with currently available approaches,” Ultragenyx CEO Emil D. Kakkis, M.D., Ph.D., said in a statement. “The joint program combines Arcturus’ technology platform, which we believe solves some of the key issues associated with mRNA therapeutics, with Ultragenyx’s expertise in rare disease drug development.” Full article

PR: Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases
“The Ultragenyx-Arcturus partnership is an ideal combination to leverage the potential of mRNA therapeutics to provide important new treatments for rare disease patients,” said Joseph E. Payne, President and CEO of Arcturus Therapeutics. “Arcturus is thrilled to work with Ultragenyx, one of the premier rare disease companies, to identify treatments for challenging rare disease targets using our messenger RNA therapeutics platform.” Full release

October 29th, 2015|
X